Referee #1:
There is (partly controversial) data in the literature demonstrating that TLR9 processing is required for TLR9 activation. Li et al. provide the first extensive analysis of DNA-binding to the cleaved version of the TLR9 ectodomain..
The authors find the truncated TLR9 ectodomain to be a monomer in solution. The authors claim that DNA ligands with phosphodiester and phosphorothioate backbones bind to TLR9 by distinct mechanisms: PD-ODN induce TLR9 dimerization in a sequence-independent manner whereas PS-ODN induce the formation of large TLR9-DNA aggregates. The presence of DNA-binding proteins such as HMGB1 or the histones H2A and H2B significantly enhanced DNA-binding to the cleaved version of TLR9. According to the authors, this enhanced binding could be explained by to the DNA bending enforced by HMGB1, H2A, and H2B.
A thorough study of DNA-binding to the cleaved version of TLR9 will certainly provide important insights into the molecular activation mechanism of TLR9. Furthermore, the potential of ODNs as vaccine adjuvants as well as the involvement of self-DNA in autoimmune disease makes it important to further investigate the binding modes of different DNA ligands and to elucidate the influence of DNA-binding proteins.
However, a direct comparison between full-length TLR9 and the cleaved version of TLR9 would have been absolutely critical to draw conclusions regarding the differences between these two TLR9 versions. This is especially important as the results (e.g. Kd values) partly differ significantly from former reports in which the full-length version of TLR9 was used. Compared to former reports, different expression systems and purification methods were used. In addition, the assays used to determine binding differ. To exclude that different experimental setups are responsible for the observed differences rather than the fact that the cleaved version of TLR9 was studied instead of the full-length form, the two forms should be compared in the same experimental setup. The work in this manuscript is technically elegant and well performed. However, the relevance of the reported interactions for the activation of the receptor in cells is questionable given the particular microenvironment in which the ligand/receptor interaction takes place. Thus, it would be critical to perform an analysis with the truncated version of the TLR9 receptor used for the binding studies and test the relevance for activation of the receptor in a gain-of-function system, such as the HEK expression system.
In addition, the following points require clarification: -It is claimed that the expression of mTLR9-cECD resulted in normal glycosylation. For some studies, however, TLR9 was deglycosylated by treatment with PNGase F. Therefore, a clear labeling and proper explanations when and why dgTLR9 vs gTLR9 was used should be provided throughout the whole manuscript. -The ligands used in this study are no commonly used TLR9 ligands. Why were these ligands chosen?
Specific comments Table 1 -Data for glycosylated or deglycosylated TLR9? -Kd values are significantly higher than the Kd values found in previous studies → include fulllength TLR9 as a control to see if high Kd values can be reproduced under the experimental conditions chosen in this study -Controls for nonspecific binding are missing (e.g. irrelevant receptor/ligand) -Raw data for all ligands should be included in the supplementary table Fig. 1A -This is the deglycosylated protein. This should be indicated in the figure (not only in material and methods). How does the glycosylated protein look like? -Control of dimeric protein is missing (would be good to see that experimental conditions allow dimerization) -A direct comparison to the full-length version would be crucial to support the conclusion that the N-terminal region of the ectodomain is responsible for the dimerization observed in former studies Shouldn't an excess of DNA (or a 1:1 ratio) saturate TLR9 so that oligomerization cannot occur anymore? If this is true, why is the biggest change seen with the highest molar ratio? An excess of ligand should lead to inhibition of dimerization.
-Difference between 14PD and 14PS interesting, but as 14PD was stated to not bind at all, this might not be a good example to state a general difference between PD-ODN and PS-ODN, binding data of 14PS are missing This paper describes characterization of the purified C terminal fragment of TLR9, binding affinities of various ligands, and dimerization kinetics of the protein. While such studies have been performed with the full-length protein, the current study is the first to examine cleaved TLR9. For this reason this manuscript will be important for investigators in the field, especially those studying the role of endosomal TLRs in autoimmunity or those targeting TLR9 for therapeutic applications. The work is very nice, and the manuscript is well written. My only substantive comment is that it would be nice to see side-by-side comparisons between the C terminal fragment and the full-length receptor. If the authors have purified full-length TLR9, then I would encourage them to include some data with this protein. They refer several times to binding measurements performed by other groups with the fulllength receptor, but it is difficult to know whether the differences that they measure with their cleaved protein are real or a result of lab to lab differences. This is a minor issue, but these data would increase the impact of the paper.
Referee #3: S.s.DNA recognising TLR9 is endosomally expressed and proteolytically cleaved by endosomal proteases including cathepsin to generate -according to recent data -the active receptor.Whether the cleaved C-terminal fragment has any biological function is ill understood. Here the authors expressed this cleaved fragment (residues 474-824)in a baculovirus-insect cell expression system and used state of the art biophysical technology to analyse in vitro possible functions.At surprise in solution the cleaved fragment per se is a monomer and phosphodiester Oligonucleotides (ODN's) induce dimerisation in a sequence independant manner (no CpG dependancy) while "stiky"phosphorothioate ODN's cause large aggregates. Furthermore DNA curvature inducing proteins such as HMGB1 or certain histones enhanced TLR9 binding as if TLR9 senses curved DNA backbones.The data per se look convincing to me. An unusual aspect of the discussion of the data is -possibly reviewers don't like this -that the authors take as "granted" published data and use their own novel data together with published data to "build" a novel model for TLR9 actvation. Accordingly, cleavage of TLR9 is necessary to undergo ligand-induced conformational change to gring the TIR domain in close proximity -currently believed to iniate TLR9 signalling.Again this synthesis of conclusions I consider as valid and novel Clearly this MS fosters our molecular understanding of TLR9 activation, since it appears to explain the requierement of TLR9 cleavage, Referee #1:
Major Critiques
"a direct comparison between full-length TLR9 and the cleaved version of TLR9 would have been absolutely critical to draw conclusions regarding the differences between these two TLR9 versions… To exclude that different experimental setups are responsible for the observed differences rather than the fact that the cleaved version of TLR9 was studied instead of the full-length form, the two forms should be compared in the same experimental setup."
The full-length ectodomain of TLR9 is notoriously difficult to express and is poorly behaved in solution. Moreover, the experimental approaches that we used (ITC, FP, AUC, CD), while providing a wealth of biophysical data, require relatively large quantities of soluble protein (of the order of 1 mg of pure protein). Nevertheless, to address the referee's critique, we employed three different strategies to purify the full-length TLR9 ectodomain: (1) purification of histidine-tagged TLR9-ECD from insect cells using a baculovirus expression system; (2) purification of TLR9-ECD fused to an IgG Fc domain from transiently transfected human HEK293 cells; and (3) purification of the N-terminal cleavage fragment of TLR9 (TLR9-nECD) from insect cells, for use in combination with our previously purified TLR9-cECD material to reconstitute the full-length cleaved ectodomain. Unfortunately, all three of the approaches failed to yield sufficient quantities of soluble protein for a side-by-side comparison with TLR9-cECD using the approaches listed above.
We cite two studies that used purified full-length TLR9 to measure ligand binding: Latz et al. (2007) and Haas et al. (2008) . Both studies used a human cell line cloned from a single colony to select for stable expression of the full-length TLR9 ectodomain fused to an IgG Fc domain. We do not have this cell line in our laboratory, but based on our transient transfection experiments with a similar construct, this approach would not have yielded TLR9-Fc in sufficient quantities for a direct comparison with TLR9-cECD using our experimental setup. Moreover, in both of the cited studies, the TLR9-Fc protein was evidently insoluble in the absence of detergent since it had to be purified and stored in the presence of the zwitterionic detergent CHAPS, which would have interfered with ITC and AUC analysis (detergent micelles typically release heat as they disassemble when they are diluted). Furthermore, as Latz et al. point out in their paper, Fc domains form dimers and the resulting "forced dimerization" of TLR9-Fc will certainly affect the oligomeric state of the protein and may also affect its ligand binding affinities, for example due to cooperative binding.
We note that both the Latz et al. and Haas et al. studies measured TLR9 ligand binding using an amplified luminescent proximity homogenous assay (AlphaScreen; Perkin Elmer) or by surface plasmon resonance (SPR). Both of these techniques require much smaller quantities of protein than the approaches we used in our study, however neither of AlphaScreen nor SPR provide insight on the oligomeric state of the protein, the stoichiometry of binding, or the relative contributions of enthalpy and entropy to binding. Moreover, SPR is susceptible to various kinds of experimental artifacts, for example due to mass action effects or due to nonspecific binding of protein to the chip, and AlphaScreen is a proprietary technology that requires a costly instrument, which we do not have access to.
Although we agree that a direct comparison the binding affinities of TLR9-cECD and fulllength TLR9 would have been helpful, a direct comparison of the cell signaling activities of cleaved and full-length TLR9 is more biologically relevant. As requested in the next critique, we now provide such a direct comparison in a new figure (Fig. 7) . Thus, the new cell signaling data also addresses the current critique by providing a direct comparison of the biological activities of cleaved and full-length TLR9. To address this critique, we obtained HEK293 cells stably expressing an NF-κB-dependent luciferase reporter gene (a kind gift from Prof. Ruslan Medzhitov). For a direct comparison of the signaling activities of full-length and truncated TLR9, we transfected the cells with either full-length TLR9 or the C-terminal cleavage fragment of TLR9 (i.e. TLR9-cECD followed by the transmembrane and TIR domains). We then measured signaling activation in the cells in response to stimulated with two different PS-ODN DNA ligands. We found that the C-terminal cleavage fragment is capable of activating signaling, albeit at lower levels than the full-length receptor. These data are consistent the original mechanism of TLR9 activation that we proposed in the Discussion (see Fig. 8 ) based on our in vitro data and on previous studies. In this mechanism, the N-terminal fragment of the cleaved receptor is required for a full signaling response.
We present these cell-signaling data in a new figure (now Fig. 7) . We have added a paragraph in the Results section describing our cell signaling data, under the new subheading "The Cterminal cleavage fragment of TLR9 activates NF-κB signaling". We also inserted a sentence in the Discussion (p. 13) to tie the signaling data into the discussion, and we inserted a section at the end of the Materials and Methods describing how the cell signaling studies were performed. We now clearly specify throughout the manuscript whether the native mTLR9-cECD was used or whether the protein was deglycosylated with PNGase F. Details of the changes that were made to the tables, figures and figure legends and text are given below in the responses to Comments #3, #7, #10, #12 and #14. We replaced the "Fluorescent label" column in Table 1 with a column indicating whether or not TLR9 was deglycosylated, for each ligand and approach (ITC, AUC, FP) that was used. The presence of a fluorescent label is still indicated in the name of the ODN, as noted in the footnotes for Table I .
"Table 1: Kd values are significantly higher than the Kd values found in previous studies…; include full-length TLR9 as a control to see if high Kd values can be reproduced under the experimental conditions chosen in this study"
This comment has been addressed above (see Major Critiques, comment #1). Based on the results from our new cell signaling studies (see Major Critiques, comment #2) and on our proposed TLR9 activation mechanism (Fig. 8) , we would expect that the binding affinities for full-length TLR9-ECD would be consistent with previous studies, and higher than those reported in this study for TLR9-cECD. A recent study by Chen et al. (2011) reports Kd values for ligand binding by full-length TLR9 in live cells that are slightly higher than the previously reported Kd values (but still lower than our Kd values for TLR9-cECD). This study is now cited on p. 10.
"Table 1: Controls for nonspecific binding are missing (e.g. irrelevant receptor/ligand)"
We now include controls for nonspecific binding in which we titrated bovine serum albumin (BSA) into solutions of two different fluorescently labeled ligands, one PD-ODN and one PS-ODN, and measured the fluorescence anisotropy polarization (FP) of the fluorophore. No binding was observed. This is noted in the text (p. 9). The binding curves for these controls are shown in two new panels in Supplementary Figure 2. 6.
"Table 1: Raw data for all ligands should be included in the supplementary table"
The supplementary table presents the raw data for the AUC experiments. We have added the raw AUC data for 50LIGPD and ds50LIGPD to the supplementary table. These were the only ligands that were missing from the table.
"Fig. 1A: This is the deglycosylated protein. This should be indicated in the figure (not only in material and methods). How does the glycosylated protein look like?"
The glycosylation state of the protein is now noted in the legend to Fig. 1 . We have added a new panel in Fig. 1 (now Fig. 1A) showing a size-exclusion chromatogram with the corresponding SDS-PAGE gel for the glycosylated protein. The glycosylated protein elutes slightly earlier from the size-exclusion column, consistent with the increased radius of the molecule due to the glycans. Several glycosylation states can also be distinguished on the gel as expected for the glycosylated protein.
"Fig. 1A: Control of dimeric protein is missing (would be good to see that experimental conditions allow dimerization)"
Fig . 1A shows the absorbance at 280 nm of the eluate of a size-exclusion chromatography column loaded with TLR9-cECD. The running buffer for the column was 20 mM MES pH 5.6, 0.1 M NaCl, 2 mM beta-mercaptoethanol. The column was run at 4˚C. The pH and ionic strength of the buffer are very similar to the physiological conditions in late endosomes. Sizeexclusion chromatography well established and accepted as a mild and non-denaturing protein purification procedure. Indeed we and others have purified many oligomeric complexes using similar conditions and approaches. It therefore our opinion that adding a chromatogram of an unrelated dimeric protein to Fig. 1 is unnecessary and could be confusing to the readers.
"Fig. 1A: A direct comparison to the full-length version would be crucial to support the conclusion that the N-terminal region of the ectodomain is responsible for the dimerization observed in former studies"
This has been addressed above (see "Major Critiques").
10. " Fig. 1B : glycosylated or deglycosylated protein?"
Deglycosylated protein was used. This is now noted in the legend.
"Fig. 2: why is LIGPD used and not a common TLR9 ligand?"
This has been addressed in the response to Comment #2.
12. " Fig. 2 : Glycosylated or deglycosylated TLR9?" Deglycosylated TLR9 (dgTLR9) was used for all four panels. This is now noted in the legend.
"Fig. 2: Comparison between LIGPD and INHPD difficult because INHPD not only G-tetrad, but also significantly shorter"
LIGPD is a 20mer and INHPD is a 15mer, so there is indeed a significant length difference. The lengths and sequences of these two ODNs were selected because they have been used in recent and relevant studies on TLR9 signaling (Latz et al. 2007 , Ashman et al. 2011 , Haas et al. 2008 , Kindrachuck et al. 2007 ; see Comment #2 above).
Despite the length difference between LIGPD and INHPD, the comparison of ITC TLR9-ECD binding profiles for the two ODNs in Fig. 2 is informative. Indeed, while the binding affinities of the two ODNs for TLR9 are similar, INHPD has a much smaller binding enthalpy (∆H) but also a much smaller entropic penalty for binding. As discussed in the text, these effects suggest that INHPD has an inherently more rigid backbone than LIGPD and that this rigidity restricts the number of favorable contacts INHPD can form with TLR9-cECD. The length difference between INHPD and LIGPD cannot by itself explain a difference in rigidity between the two ODNs. In contrast, the G-tetrad is likely to increase rigidity through the increased bulk and base-stacking interactions of the four consecutive guanosine bases.
14. " Fig. 3 : TLR9 or dgTLR9 used?" dgTLR9 in panel A and TLR9 panel B. The use of both glycosylated and deglycosylated forms allows a direct comparison of the AUC profiles of the two protein-only samples (second curve from the top in panels A and B). The AUC profiles of TLR9 and dgTLR9 are similar, with the glycosylated protein sedimenting slightly faster than dgTLR9 (2.6 S vs. 2.3 S), as expected from the reduced bulk of dgTLR9 and consistent with size-exclusion chromatography profiles for the two protein samples.
In order to provide a direct comparison between binding of LIGPS to TLR9 and dgTLR9, we have added a new AUC curve for dgTLR9 binding to LIGPS (Fig 3B, bottom curve in revised manuscript). The labeling in Fig. 3 and the figure legend were modified to specify which form of the protein was used for each experiment.
15. " Fig. 3 : What is the peak before peaks A/B at the very front?"
The very first peak that appears in most AUC curves at approximately 0.5 S corresponds to prematurely truncated oligonucleotides (or to another small-molecule contaminants) from the oligonucleotide synthesis reaction. We have added a sentence pointing this out in the legend to Fig. 3 .
"Fig. 4: In general: Shouldn't an excess of DNA (or a 1:1 ratio) saturate TLR9 so that oligomerization cannot occur anymore? If this is true, why is the biggest change seen with the highest molar ratio? An excess of ligand should lead to inhibition of dimerization."
The effect of an excess of ligand on the oligomerization state of TLR9 will depend on the cooperativity of binding. In the absence of any cooperativity, a large excess of ligand should indeed result in TLR9 binding almost exclusively as a monomer since very few TLR9 molecules would bind to the same ligand. Negative cooperativity (when ligand binding inhibits oligomerization) would amplify this effect. However, with positive cooperativity, TLR9 would bind preferentially to a preformed TLR9-ligand complex rather than to free ligand, and TLR9 would form oligomers even with an excess of ligand.
While our AUC data (Fig. 3) rules out negative cooperativity of TLR9-ligand binding (since low ligand concentrations promote oligomerization), we were not able to confirm the presence of positive cooperativity directly using AUC because we were constrained in our experimental setup by the relatively low binding affinity to use high protein concentrations (in the micromolar range). To generate an excess of ligand while remaining concentrations above the Kd we would have had to use ligand concentrations that would have exceeded the optical detection limit of our instrument (1.2 AU). Fig. 4 does not report directly on the oligomerization state of the protein but rather on secondary structure changes that accompany ligand binding. In principle, the saturable changes in the CD spectra in Fig. 4A and 4B could result from changes in the secondary structure of monomeric TLR9 as it binds to the PS-ODNs. However, we know from our AUC data that TLR9 forms oligomers at low ligand:protein molar ratios, and the changes in the CD spectra in Fig. 4 are progressive and occur in the same direction as ligand is titrated in. Thus, together these data suggest that PS-ODNs induce TLR9 oligomerization, which is accompanied by changes in the secondary structure of TLR9, as we state in the text. This is consistent with positive cooperativity of TLR9-ligand binding but we refrained from claiming positive cooperativity in the text due to the indirect nature of the readout on oligomerization of the CD data presented in Fig. 4. 17. " Fig. 4 Panels A and C of Fig. 4 compare the CD spectra for LIGPS and LIGPD, two ODNs with identical sequences but with PS and PD backbones, respectively. LIGPS and LIGPD both bind DNA. Our conclusions on the differences between PS-and PD-ODNs in the text are based mostly on the differences between LIGPS and LIGPD and between INHPS and INHPD. However, one of the differences between PS-and PD-ODNs is that the length requirement for binding is different, since 14PS binds TLR9-cECD but not 14PD even though both are 14mers. This is why the data for 14PS and 14PD are discussed in the text and presented in Fig. 4 . To eliminate any risk of readers concluding that 14PS/14PD differences are the sole basis for our conclusions, we now explicitly state on p. 10 that "Titration with PS-ODNs, including LIGPS and 14PS, reduced the intensity of the [CD] spectrum…". We assume that the referee is referring to the lanes labeled "0, 1, 10, 100" in 5A and "0.01, 0.1, 1" in 5B. The features that look like one weak band at the top each lane in 5A, and two distorted weak bands at the top of each lane in 5B are in fact small amounts of TLR9-DNA complexes that remained in the loading wells and did not enter the gel at all. The extra "bands" are simply the outline of the loading wells. In both Fig. 5A and 5B, most of the TLR9-DNA complexes run as a single band just one or two millimeters away from the loading well. The gels were both cast and run horizontally and the wells were formed with Teflon combs. We did not crop out the wells in order to illustrate that some of the TLR9-DNA complexes did not enter the gel. This is presumably due to aggregation of the complexes and/or to a net neutral or positive charge of complexes with larger numbers of TLR9 molecules bound to the DNA. As noted in the figure legend, protein staining (not shown) reveals that unliganded TLR9 does not enter the agarose gel, due to the net positive charge of the protein. The Fig. 5 legend has been expanded to clarify that the features at the top of the two gels are due to TLR9-DNA complexes that did not enter the gel and remained in the loading well.
19. " Fig It is a valid point that our data do not directly demonstrate that DNA bending is responsible for the enhancement of DNA binding by TLR9 in the presence of HMGB1 and core histones. However, as we discuss in the text, HMGB1 and histones H2A-H2B share no structural or sequence similarities and have in common only that they bind DNA non-specifically, and in doing so induce bending of the DNA (Luger et al. 1997; Paull et al. 1993; Pil et al. 1993 , as cited in the text). As discussed in the response to Comment #13, we note that the data in Fig. 2 suggest that INHPD is a more rigid ligand than LIGPD, and that this rigidity results in a smaller binding enthalpy. This provides additional (albeit still somewhat indirect) evidence that flexibility of the DNA backbone is required for optimal binding to TLR9-cECD.
We state in the text that based on the enhancement of DNA binding by HMGB1 and H2A-H2B "we therefore hypothesized that the DNA curvature-enhancing activities of these proteins may enhance DNA recognition by TLR9." We stand by this hypothesis, however, we acknowledge that our data does not fully test it and we have slightly modified the text on p. 11 accordingly. Instead of "To test this hypothesis…" the text now reads "In support of this hypothesis…".
We are looking forward to evaluating the effect of DNA bending on TLR9 recognition more directly and systematically using protein-free DNA ligands with fixed curvatures, in future studies that fall beyond the scope of the current study.
(Note: this comment was truncated in our communication from the editor and we are assuming the referee was referring to bending of the DNA.)
21. " Supplementary Fig. 1 The length, sequence and double-stranded nature of 601H2 were chosen to optimize histone binding as discussed in the text, so these properties were constrained in 601H2. However, some of these properties were dissected systematically with the 50LIGPD ligand. For 50LIGPD, we performed a direct comparison of single-stranded versus double-stranded ligand. The sequence of LIGPD is also contained within the sequence of 50LIGPD, and 50LIGPD does not contain any additional CG motifs, so a comparison of LIGPD versus single-stranded 50LIGPD provides a direct readout on length variation.
There are certainly a large number of additional permutation of length, sequence and secondary structure that we have not tested, and further dissection is warranted in future studies. However, the 15 oligonucleotides that were used in this study sample lengths of 14, 15, 20, 31 and 50 bp, include various sequence motifs and chemical modifications and include both single-and double-stranded ligands. Specific pairs of ligands can be (and were) used in our study to dissect the effect of each of these properties one at a time. Our study therefore contributes meaningfully and significantly to our understanding of each of these ligand properties.
"Supplementary Fig. 1: label peaks in B and give explanation what the single peaks represent"
TLR9cECT) is functional -see the work of Ewald and others). Here the authors describe that in vitro PS-ODN's bind to TLR9cECT and cause aggregation -while PD-OdN's bind but cause dimerisation of TLR9-cECT. Furthermore compelling evidence is provided that DNA curvature inducing proteins such as HMGB1 and certain histones enhance binding of DNA-ligands to TLR9. The impact of the amended MS is fostered by addition of Fig 7 showing that transfection of TLR9-cECT causes poor NFkB activation as compared to that of full length TLR9. Altogether these data allow the authors to propose a novel TLR9 activation model in which -after cleavage -both the Cterminal as well as the N-terminal "cleaved "fragments bind "curved" DNA.
In the first review process a major criticism raised was that a direct comparison between full-length and the cleaved version of TLR9 is essential. The authors convincingly state that their techniques (ITC, FP, AUC, CD) require large quantities (in the order of 1 mg) of pure protein. All attempts to obtain and to purify such large quantities of protein, however, failed, unfortunately. Personally I accept these statements, based on personal experience/failures on this issue. At least in part, the "biology" data of the new Fig.7 compensate for this. Finally, the MS heightened its impact by thoroughly answering all the specific comments of the first referee. The minor issues of Referee 3 and 2 have also been dealt with well.
